Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;189(6):1083-1092.
doi: 10.1111/bjh.16489. Epub 2020 Feb 17.

Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study

Sara Ekberg  1 , Karin E Smedby  1   2 , Ingrid Glimelius  1   3 , Herman Nilsson-Ehle  4 , Christina Goldkuhl  5 , Catharina Lewerin  4 , Mats Jerkeman  6 , Sandra Eloranta  1
Affiliations

Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study

Sara Ekberg et al. Br J Haematol. 2020 Jun.

Abstract

Non-Hodgkin lymphoma (NHL) prognosis has improved in recent years, yet the number of patients living with the diagnosis, i.e. the prevalence, has seldom been reported. The prevalence provides a measure of the burden of disease, useful for healthcare planning and to optimise resource allocation. We provide a systematic presentation of temporal trends in absolute numbers of prevalent patients by NHL subtypes, linking them to trends in incidence, survival and mortality. Patients diagnosed 2000-2016 were identified in the national Swedish lymphoma register. Incidence and mortality rates, relative survival and prevalence were estimated for NHL overall and for major clinical and morphological subtypes. Poisson regression was used to test for temporal trends. Increasing incidence and improved survival have led to a 47% increase in the five-year prevalence of NHL overall in 2016 compared to 2004. An increasing prevalence was observed for all investigated subtypes during the study period, but most notably for diffuse large B cell lymphomas among aggressive subtypes (66%), and marginal zone lymphomas among indolent subtypes (135%). This dramatic increase in NHL prevalence underscores the need to develop and evaluate alternative follow-up schemes to use resources efficiently and still ensure optimal care of lymphoma survivors.

Keywords: incidence; non-Hodgkin lymphoma; prevalence; survival.

PubMed Disclaimer

References

    1. Aschebrook-Kilfoy, B., Caces, D.B., Ollberding, N.J., Smith, S.M. & Chiu, B.C. (2013) An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leukaemia & Lymphoma, 54, 1677-1683.
    1. Bosetti, C., Levi, F., Ferlay, J., Lucchini, F., Negri, E. & La Vecchia, C. (2008) Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? International Journal of Cancer, 123, 1917-1923.
    1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. & Jemal, A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
    1. Chaganti, S., Illidge, T., Barrington, S., Mckay, P., Linton, K., Cwynarski, K., McMillan, A., Davies, A., Stern, S. & Peggs, K.; British Committee for Standards in Haematology. (2016) Guidelines for the management of diffuse large B-cell lymphoma. British Journal of Haematology, 174, 43-56.
    1. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.

Publication types

LinkOut - more resources